Jakavi® (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases and approved in more than 80 countries, including the European Union, Canada, Japan and countries in Asia, Latin and South America for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic MF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF)\(^1\). The Canadian and European Union approvals of Jakavi in MF, PPV-MF or PET-MF were supported by two pivotal Phase III trials (COMFORT-I and COMFORT-II) comprising the largest clinical trial program in myelofibrosis to date\(^2,3\).

COMFORT-II (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy) is a European study comparing the efficacy, safety and tolerability of Jakavi to conventional therapy at 48 weeks in patients with myelofibrosis, a life-threatening blood cancer arising in the bone marrow\(^4,5,6\).

The COMFORT-II study evaluated Jakavi in patients with primary myelofibrosis, PPV-MF, or PET-MF who were either resistant or refractory to, intolerant of, or in the investigators’ opinion not candidates for available therapy and for whom treatment of myelofibrosis was indicated\(^3\). A long-term follow-up update was designed to evaluate the long-term efficacy and safety of Jakavi therapy in patients with myelofibrosis at a two-year and three-year follow-up\(^6,7\).

**Primary Study Design (48 Weeks)**

The randomized, open-label Phase III study included 219 patients with primary myelofibrosis, PPV-MF or PET-MF in 56 study locations in Europe. Two-thirds (146 patients) received Jakavi twice daily and one-third (73 patients) received conventional therapy, which was administered at doses and schedules determined by the investigator.

The trial consisted of a randomized treatment phase and an optional extension phase that consisted of a crossover control group\(^4\). Conventional therapy was selected by the investigator for each subject and could have included a combination of available agents to treat the disease and/or its symptoms. Further, therapy could have been changed at any time during the treatment phase. No experimental agents (e.g., those not approved for the treatment of any indication) could have been used\(^4\).
### Study Design and Outcomes

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Long-Term Updates</th>
</tr>
</thead>
</table>
| **Primary Study (48-Week Analysis)**
- The primary endpoint was the proportion of patients achieving ≥35% reduction in spleen volume from baseline to week 48 as measured by MRI (or CT scan in applicable patients).
- Secondary endpoints included:
  1. Proportion of patients achieving a ≥35% reduction of spleen volume from baseline to week 24 as measured by MRI (or CT scan in applicable patients).
  2. Duration of maintenance of a ≥35% reduction from baseline in spleen volume (measured baseline and every 12 weeks up to week 72, after which this outcome was evaluated every 24 weeks).
  3. Change in bone marrow histomorphology.
  4. Leukemia-free survival.
  5. Progression-free survival.
  6. Overall survival. |
| **Two-Year Follow-up Analysis**
- This update was designed to evaluate long-term efficacy and safety of Jakavi therapy in patients with myelofibrosis during a two-year follow-up period. |
| **Three-Year Follow-up Analysis**
- This analysis evaluated efficacy and safety of Jakavi therapy in patients with myelofibrosis during a three-year follow-up period.
- A total of 45.2% of patients remained on the Jakavi treatment arm after three years, while all patients randomized to conventional therapy discontinued treatment. Of patients on conventional therapy, 61.6% crossed over to the Jakavi treatment arm, with 48.9% of these patients ongoing in the extension phase of the study. |

### Study Outcomes

<table>
<thead>
<tr>
<th>Study Outcomes</th>
<th>Long-Term Updates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jakavi produced a spleen size reduction of 35% or greater (roughly equivalent to a reduction in spleen size by 50%) in 28% of patients compared to 0% of patients in the conventional therapy group at 48 weeks (p&lt;0.001).</strong></td>
<td></td>
</tr>
<tr>
<td><strong>At week 24, 32% of patients treated with Jakavi demonstrated a 35% or greater spleen size reduction compared to 0% of patients treated with conventional therapy (p=0.001) for the key secondary endpoint.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>No major changes in marrow histomorphologic features were observed in a pre-specified secondary analysis of data from patients receiving any therapy.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>In the analyses of leukemia-free survival and overall survival, there were 10 events in total (all of which were deaths): 6 events (4%) with Jakavi, as compared with 4 events (5%) with conventional therapy.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Additionally, Jakavi was associated with improvements in myelofibrosis symptoms at each evaluation as compared to conventional therapy.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Jakavi was associated with sustained reductions in splenomegaly (enlarged spleen).</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Overall, 48.3% of patients treated with Jakavi achieved a ≥35% reduction in spleen size, with results sustained over two years.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>In a rigorous intent-to-treat analysis, Jakavi-treated patients showed a reduced risk of death compared to patients receiving conventional therapy (HR=0.51; 95% CI, 0.26-0.99; p=0.041).</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Jakavi continued to improve overall survival and demonstrated sustained reduction in spleen size compared to conventional therapy.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Overall, 51.4% of patients treated with Jakavi achieved a ≥35% reduction from baseline in spleen volume.</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Jakavi-treated patients showed a 52% reduced risk of death compared to patients receiving conventional therapy (HR=0.48; 95% CI, 0.28-0.85; p=0.009).</strong></td>
<td></td>
</tr>
</tbody>
</table>
About Jakavi
Jakavi (ruxolitinib) is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. Jakavi is approved by the European Commission for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea and for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi is approved in more than 80 countries for patients with myelofibrosis, including countries in the European Union, Canada, Japan and countries in Asia, Latin and South America. Additional worldwide regulatory filings are underway in myelofibrosis and PV.

Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States. Jakavi is marketed in the United States by Incyte Corporation as Jakafi® for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea and for the treatment of patients with intermediate or high-risk myelofibrosis.

The recommended starting dose of Jakavi in PV is 10 mg given orally twice daily. The recommended starting dose of Jakavi in myelofibrosis is 15 mg twice daily for patients with a platelet count between 100,000 cubic millimeters (mm$^3$) and 200,000 mm$^3$, and 20 mg twice daily for patients with a platelet count of $>$200,000 mm$^3$. Doses may be titrated based on safety and efficacy. There is limited information to recommend a starting dose for myelofibrosis and PV patients with platelet counts between 50,000/mm$^3$ and $<$100,000/mm$^3$. The maximum recommended starting dose in these patients is 5 mg twice daily, and patients should be titrated cautiously.$^8$

Jakavi is a registered trademark of Novartis AG in countries outside the United States. Jakafi is a registered trademark of Incyte Corporation. The safety and efficacy profile of Jakavi has not yet been established outside the approved indications.

Jakavi Important Safety Information for Treatment of Myelofibrosis (MF) and Polycythemia Vera (PV)

Jakavi can cause serious side effects, including a decrease in blood cell count and infections. Complete blood count monitoring is recommended. Dose reduction or interruption may be required in patients with any hepatic impairment or severe renal impairment or in patients developing hematologic adverse reactions such as thrombocytopenia, anemia and neutropenia. Dose reductions are also recommended when Jakavi is co-administered with strong CYP3A4 inhibitors or fluconazole. Use of Jakavi during pregnancy is not recommended, and women should avoid becoming pregnant during Jakavi therapy. Women taking Jakavi should not breast feed. Progressive multifocal leukoencephalopathy (PML) has been reported. Physicians should be alert for neuropsychiatric symptoms suggestive of PML. Hepatitis B viral load (HBV-DNA titer) increases have been reported in patients with chronic HBV infections. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines. Non-melanoma skin cancer (NMSC) has been reported in Jakavi treated patients. Periodic skin examination is recommended. Very common adverse reactions in MF (>10%) include urinary tract infections, anemia, thrombocytopenia, neutropenia, hypercholesterolemia, dizziness, headache, alanine aminotransferase increased and aspartate aminotransferase increased, constipation and hypertension.

Please see full Prescribing Information available at www.jakavi.com.

References